New heart attack treatment aims to slash cholesterol fast

NCT ID NCT07102628

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing if starting a cholesterol-lowering medication called inclisiran very early after a heart attack or severe chest pain (acute coronary syndrome) is safe and effective. About 300 hospitalized patients will receive either inclisiran or a placebo (dummy injection) along with their standard care. The main goal is to see if the drug significantly lowers 'bad' cholesterol (LDL-C) levels 150 days after starting treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-••••

Locations

Novartis Investigative Site
RECRUITING

Clayton, Victoria, 3168, Australia
Novartis Investigative Site
RECRUITING

Luoyang, Henan, 471002, China
Novartis Investigative Site
RECRUITING

Xuzhou, Jiangsu, 221003, China
Novartis Investigative Site
RECRUITING

Wenzhou, Zhejiang, 325000, China
Novartis Investigative Site
RECRUITING

Guangzhou, 510280, China
Novartis Investigative Site
RECRUITING

Shanghai, 200032, China
Novartis Investigative Site
RECRUITING

Shanghai, 200120, China
Novartis Investigative Site
RECRUITING

Nantes, 44093, France
Novartis Investigative Site
RECRUITING

Poitiers, 86021, France
Novartis Investigative Site
RECRUITING

Hong Kong, Hong Kong, 999077, Hong Kong
Novartis Investigative Site
RECRUITING

Belagavi, Karnataka, 590010, India
Novartis Investigative Site
RECRUITING

Nashik, Maharashtra, 422005, India
Novartis Investigative Site
RECRUITING

Bikaner, Rajasthan, 334003, India
Novartis Investigative Site
RECRUITING

Chikushino-shi, Fukuka, 818-8516, Japan
Novartis Investigative Site
RECRUITING

Kitakyushu, Fukuoka, 8028555, Japan
Novartis Investigative Site
RECRUITING

Kamakura, Kanagawa, 247-8533, Japan
Novartis Investigative Site
RECRUITING

Sagamihara, Kanagawa, 252-0375, Japan
Novartis Investigative Site
RECRUITING

Bunkyo Ku, Tokyo, 1138431, Japan
Novartis Investigative Site
RECRUITING

Gdansk, 80-214, Poland
Novartis Investigative Site
RECRUITING

Seoul, Seoul, 06351, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 07804, South Korea
Novartis Investigative Site
RECRUITING

Salamanca, 37007, Spain
Novartis Investigative Site
RECRUITING

Seville, 41013, Spain
Novartis Investigative Site
RECRUITING

Bern, 3010, Switzerland
Novartis Investigative Site
RECRUITING

Geneva, 1211, Switzerland
Novartis Investigative Site
RECRUITING

Lucerne, 6000, Switzerland

Conditions

Explore the condition pages connected to this study.

ACUTE CORONARY SYNDROME